A growing body of evidence suggests that patients with cancer have an increased risk of severe COVID-19 infection and related complications. As such, NANETS, the North American Neuroendocrine Tumor Society, supports the plan for COVID-19 vaccination for patients with neuroendocrine neoplasms (NENs), including well differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). NEN survivors and patients with NENs on observation or undergoing cancer treatment should be offered COVID-19 vaccination as long as any components of the vaccine are not contraindicated. READ MORE
